MIDDLE EAST AND ASIA PACIFIC ANTIBODY DRUGS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Antibody drugs are established first-line treatment modalities for a range of cancer and other diseases. On the basis of type, the Middle East and Asia Pacific antibody drugs market is segmented into Monoclonal Antibody, Polyclonal Antibody, Bispecific Antibody, Biosimilars, Single Domain Antibody, CAR-T, and Anti-idiotype Antibody.

Monoclonal Antibody are laboratory-produced antibodies designed to recognize and bind to specific receptors found on the surface of cells. Monoclonal Antibody are used in the diagnosis and treatment of various diseases including some types of cancer. Polyclonal antibodies are a heterogeneous mix of antibodies derived from the immune response of multiple B-cells, in which each one recognizes a different epitope on the same antigen. Polyclonal antibodies are composed of a mixture of antibodies that represent the natural immune response to an antigen. Biosimilar Monoclonal Antibody (mAbs) are part of the biosimilar family. They are large, complex proteins used by the immune system to identify and neutralize foreign bodies such as bacteria, viruses, and others, and are usually administered in the treatment of diseases such as cancer or rheumatoid arthritis.

Market Dynamics

The high prevalence of chronic diseases such as cancer, multiple sclerosis, asthma, rheumatoid arthritis, psoriasis, and others is expected to drive the Middle East and Asia Pacific antibody drugs market growth in the forecast period. For instance, according to the Cancer Country Profile 2020 published by the World Health Organization (WHO), the total number of cancer cases in 2018 in Bahrain was 1,048 with 603 deaths. Moreover, as per the information provided in an article published in the Journal of Clinical Medicine in 2021, Saudi Arabia has the highest prevalence of non-communicable diseases (NCDs) such as cancer, cardiovascular disease, and others, which account for 73% of the country's mortality.

Key features of the study

• This report provides an in-depth analysis of the Middle East and Asia Pacific antibody drugs market, market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Middle East and Asia Pacific antibody drugs market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies
• Key companies covered as a part of this study include Novartis AG, Amgen, Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., Johnson & Johnson Private Limited, Abbvie, Inc., Eli Lilly and Company, GlaxoSmithKline plc., Daiichi Sankyo Company, Limited, Celltrion Healthcare Co., Ltd., Mylan N.V., Boehringer Ingelheim International GmbH., Biocon, and Merck & Co., Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The Middle East and Asia Pacific antibody drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Middle East and Asia Pacific antibody drugs market

Market Segmentation

• By Type
  • Monoclonal Antibody
  • Polyclonal Antibody
  • Bispecific Antibody
  • Biosimilars
  • Single Domain Antibody
  • CAR-T
  • Anti-idiotype Antibody
• By Disease Indication
  • Oncology
  • Neurology
  • Autoimmune Disorders
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • Middle East
    • Kingdom of Saudi Arabia
    • UAE
    • Israel
    • Iran
    • Jordan
    • Turkey
    • Qatar
    • Rest of Middle East
  • Asia Pacific
    • South East Asia
    • The Philippines
    • Malaysia
    • Singapore
    • Thailand
    • Vietnam
    • Rest of South East Asia
    • Taiwan
    • Hong Kong
    • Macau
    • Japan
    • South Korea
    • India
    • Australia
    • China
    • Rest of Asia Pacific
• Key Players
  • Novartis AG
  • Amgen, Inc.
  • Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Johnson & Johnson Private Limited
  • AbbVie
  • Eli Lilly and Company
  • GlaxoSmithKline plc.
  • Daiichi Sankyo Company
  • Limited, Celltrion Healthcare Co., Ltd.
  • Mylan N.V.
  • Boehringer Ingelheim International GmbH.
  • Biocon
  • Merck & Co., Inc.